Ainos' Losses Mount Amid Revenue Growth, Cash Drains

TL;DR

**Ainos is burning cash faster than it's growing revenue, and repeated reverse stock splits are a flashing red light for investors.**

AI Summary

Ainos, Inc. (AIMDW) reported a net loss of $10,302,714 for the nine months ended September 30, 2025, a slight increase from the $10,209,149 net loss in the prior year period. Revenues significantly increased to $113,037 for the nine months ended September 30, 2025, up from $20,729 in the same period of 2024, primarily driven by new sales. Gross profit also improved to $93,390 from a gross loss of $31,945 year-over-year. However, total operating expenses rose to $9,786,141 from $9,175,704, mainly due to increased selling, general, and administrative expenses, which climbed to $4,159,627 from $3,090,056. The company's cash and cash equivalents decreased substantially to $1,128,217 as of September 30, 2025, from $3,892,919 at December 31, 2024. Ainos executed a 1-for-5 reverse stock split on June 30, 2025, to maintain Nasdaq listing compliance, following previous splits in 2022 and 2023. The company also raised $1,852,895 through an at-the-market offering during the nine months ended September 30, 2025, to bolster its financial position.

Why It Matters

Ainos' continued net losses and significant cash burn, despite revenue growth, signal ongoing financial instability for investors. The repeated reverse stock splits (three since 2022, including a 1-for-5 split on June 30, 2025) highlight persistent challenges in meeting Nasdaq's minimum bid price requirements, eroding shareholder confidence and potentially limiting institutional investment. For employees and customers, the company's precarious financial state could raise concerns about long-term viability and product development. In the competitive AI and healthcare sectors, Ainos' struggle to achieve profitability puts it at a disadvantage against better-capitalized rivals, making its strategic partnerships and product commercialization efforts critical for survival.

Risk Assessment

Risk Level: high — Ainos reported a net loss of $10,302,714 for the nine months ended September 30, 2025, and its cash and cash equivalents plummeted from $3,892,919 at December 31, 2024, to $1,128,217 at September 30, 2025. The company has also undergone three reverse stock splits since 2022, including a 1-for-5 split on June 30, 2025, specifically to maintain Nasdaq listing compliance, indicating severe stock price underperformance and potential delisting risk.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as Ainos' substantial net losses, rapid cash depletion, and history of reverse stock splits suggest significant financial distress and a high risk of further share price erosion. Monitor cash burn rates and the effectiveness of the ATM offering closely, but be prepared for continued volatility and potential delisting.

Financial Highlights

debt To Equity

N/A

revenue

$113,037

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10,302,714

eps

-$2.61

gross Margin

82.6%

cash Position

$1,128,217

revenue Growth

+443.3%

Key Numbers

• $10,302,714 — Net Loss (for the nine months ended September 30, 2025, an increase from $10,209,149 in 2024)
• $113,037 — Revenues (for the nine months ended September 30, 2025, up from $20,729 in 2024)
• $1,128,217 — Cash and Cash Equivalents (as of September 30, 2025, down from $3,892,919 at December 31, 2024)
• $9,786,141 — Total Operating Expenses (for the nine months ended September 30, 2025, up from $9,175,704 in 2024)
• $1,852,895 — Proceeds from At-the-Market Offering (net of issuance costs, for the nine months ended September 30, 2025)
• 1-for-5 — Reverse Stock Split Ratio (effectuated on June 30, 2025, to comply with Nasdaq listing rules)
• $0.64 — Net Loss Per Common Share (for the three months ended September 30, 2025, improved from $1.64 in 2024)
• $2.61 — Net Loss Per Common Share (for the nine months ended September 30, 2025, improved from $6.49 in 2024)
• $3,759,679 — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025)

Key Players & Entities

• Ainos, Inc. (company) — registrant
• Nasdaq Capital Market (regulator) — exchange for AIMD and AIMDW
• H.C. Wainwright & Co., LLC (company) — Agent for At-the-Market Offering Agreement
• Ainos, Inc. (Cayman Islands) (company) — controlling shareholder
• Taiwan Carbon Nano Technology Corporation (company) — controlling shareholder
• AI Nose (company) — proprietary scent digitization technology platform
• VELDONA (company) — low-dose oral interferon platform
• Securities Act of 1933 (regulator) — governing ATM offering
• Rule 415(a)(4) (regulator) — defines at-the-market offering

FAQ

Risk Factors

• Deteriorating Cash Position [high — financial]: Cash and cash equivalents decreased substantially to $1,128,217 as of September 30, 2025, from $3,892,919 at December 31, 2024. This significant outflow, coupled with a net loss of $10,302,714 for the nine months ended September 30, 2025, raises concerns about the company's short-term liquidity.
• Persistent Net Losses [high — financial]: Ainos reported a net loss of $10,302,714 for the nine months ended September 30, 2025, a slight increase from the $10,209,149 net loss in the prior year period. The company has not achieved profitability, indicating ongoing challenges in its business model or market penetration.
• Rising Operating Expenses [medium — operational]: Total operating expenses increased to $9,786,141 for the nine months ended September 30, 2025, from $9,175,704 in the prior year. This rise was primarily driven by a significant increase in selling, general, and administrative expenses, which grew from $3,090,056 to $4,159,627.
• Nasdaq Listing Compliance [medium — regulatory]: The company executed a 1-for-5 reverse stock split on June 30, 2025, to maintain compliance with Nasdaq listing requirements. This follows previous reverse splits in 2022 and 2023, suggesting a persistent struggle with maintaining a minimum share price.
• Reliance on Equity Offerings [medium — financial]: Ainos raised $1,852,895 through an at-the-market offering during the nine months ended September 30, 2025. This indicates a reliance on external financing to cover operational deficits, which can dilute existing shareholders.

Industry Context

Ainos operates in a highly competitive and rapidly evolving sector, likely within biotechnology or medical devices, given its focus on product sales and R&D. The industry is characterized by significant capital requirements, long development cycles, and stringent regulatory oversight. Success often hinges on innovation, effective commercialization strategies, and securing adequate funding to navigate these challenges.

Regulatory Implications

The company's need for reverse stock splits to maintain Nasdaq listing highlights the ongoing scrutiny faced by companies with low share prices. Failure to meet listing requirements could lead to delisting, severely impacting liquidity and investor confidence. Compliance with FDA or equivalent regulations for any medical products is also a critical ongoing factor.

What Investors Should Do

1. Monitor SG&A expense growth closely to assess cost control effectiveness.
2. Evaluate the sustainability of revenue growth and its contribution to profitability.
3. Assess the company's cash burn rate and future financing needs given the declining cash reserves.
4. Analyze the impact of the reverse stock split on share price performance and market perception.
5. Scrutinize the drivers behind the significant increase in revenue to determine its long-term viability.

Key Dates

• 2025-09-30: Nine Months Ended — Reporting period for significant revenue growth but continued net loss and reduced cash reserves.
• 2025-06-30: Reverse Stock Split — A 1-for-5 reverse split was executed to meet Nasdaq minimum bid price requirements, indicating past share price struggles.
• 2025-01-01: Start of Nine Month Period — Beginning of the period where revenue increased significantly, but operating expenses also rose.

Glossary

At-the-Market Offering

A type of public offering where a company sells its stock directly into the open market over a period of time, typically through an intermediary. It's often used to raise capital opportunistically. (Ainos utilized this to raise $1,852,895, indicating a need for capital to fund operations.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. Often done to increase the stock price. (Ainos performed a 1-for-5 split to comply with Nasdaq listing rules, suggesting a history of low share price.)

Selling, General, and Administrative (SG&A) Expenses

Costs incurred by a company that are not directly related to the production or procurement of goods or services. Includes marketing, salaries, rent, and utilities. (These expenses increased significantly for Ainos, contributing to the overall rise in operating expenses and net loss.)

Gross Profit

Revenue minus the cost of goods sold (COGS). It represents the profit a company makes after deducting the direct costs associated with producing its goods or services. (Ainos improved from a gross loss to a gross profit of $93,390, a positive sign despite the overall net loss.)

Year-Over-Year Comparison

Compared to the prior year period, Ainos has demonstrated significant revenue growth, increasing from $20,729 to $113,037 for the nine months ended September 30, 2025, and improved gross profit margins. However, this growth has been outpaced by rising operating expenses, particularly SG&A, leading to a slightly wider net loss. The company's cash position has also deteriorated substantially, necessitating equity financing.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 906KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-25-022312.txt ( ) — 4544KB
• aimd-20250930.xsd (EX-101.SCH) — 34KB
• aimd-20250930_cal.xml (EX-101.CAL) — 46KB
• aimd-20250930_def.xml (EX-101.DEF) — 173KB
• aimd-20250930_lab.xml (EX-101.LAB) — 290KB
• aimd-20250930_pre.xml (EX-101.PRE) — 235KB
• form10-q_htm.xml (XML) — 597KB

Financial Statements

Financial Statements 3 Condensed Balance Sheets – September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Statements of Operations – Three and nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Condensed Statements of Comprehensive Loss – Three and nine Months Ended September 30, 2025 and 2024 (unaudited) 5 Condensed Statements of Stockholders' Equity– Three Months Ended September 30, 2025 and 2024 (unaudited) 6 Condensed Statements of Stockholders' Equity– Nine Months Ended September 30, 2025 and 2024 (unaudited) 7 Condensed Statements of Cash Flows – Nine Months Ended September 30, 2025 and 2024 (unaudited) 8 Notes to Condensed Financial Statements (unaudited) 9 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 ITEM 4.

Controls and Procedures

Controls and Procedures 29 PART II: OTHER INFORMATION 30 ITEM 1.

Legal Proceedings

Legal Proceedings 30 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 31 ITEM 3. Defaults Upon Senior Securities 31 ITEM 4. Mine Safety Disclosures 31 ITEM 5. Other Information 31 ITEM 6. Exhibits 32

Signatures

Signatures 33 2 PART I - FINANCIAL INFORMATION ITEM 1. Financial Statements Ainos, Inc. Condensed Balance Sheets September 30, December 31, 2025 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 1,128,217 $ 3,892,919 Accounts receivable 62 56 Inventory, net 166,883 143,756 Other current assets 425,753 301,077 Total current assets 1,720,915 4,337,808 Intangible assets, net 20,365,899 23,748,328 Property and equipment, net 414,558 559,645 Other assets 177,968 174,418 Total assets $ 22,679,340 $ 28,820,199 Liabilities and Stockholders' Equity Current liabilities: Contract liabilities $ - $ 106,329 Convertible notes payable (including amounts of related party of nil and $ 2,000,000 as of September 30, 2025, and December 31, 2024, respectively) - 3,000,000 Accrued expenses and others current liabilities 581,356 848,615 Total current liabilities 581,356 3,954,944 Convertible notes payable - Related parties - noncurrent 11,000,000 9,000,000 Other long-term liabilities 1,053,035 348,945 Total liabilities 12,634,391 13,303,889 Commitments and contingencies - - Stockholders' equity: Preferred stock, $ 0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of September 30, 2025, and December 31, 2024, respectively - - Common stock, $ 0.01 par value; 300,000,000 shares authorized as of September 30, 2025, and December 31, 2024, 4,793,797 and 3,085,477 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively (1) 47,938 30,854 Common shares to be issued; 12,651 and nil shares as of September 30, 2025 and December 31, 2024, respectively 127 - Additional paid-in capital 73,263,397 68,644,301 Accumulated deficit ( 63,052,030 ) ( 52,749,316 ) Accumulated other comprehensive loss ( 214,483 ) ( 409,529 ) Total stockholders' equity 10,044,949 15,516,310 Total liabilities and stockholders

View Full Filing

View this 10-Q filing on SEC EDGAR